Recent Updates — LIMN

Liminatus Pharma, Inc. regained compliance with Nasdaq's minimum bid price rule after the exchange confirmed its stock closed above $1.00 for 13 consecutive trading days from August 21 to September 9, 2026. This resolution follows a transfer to The Nasdaq Capital Market on August 4, 2026, and a 1-for-50 reverse stock split effected on August 20, 2026. The matter is now closed with no further delisting risks associated with the bid price requirement. Liminatus Pharma operates in the biotechnology industry, developing immuno-oncology and cell therapy candidates.

Liminatus Pharma, Inc. held its 2026 Annual Meeting of Stockholders on August 3, 2026, where shareholders approved the ratification of Withum Smith+Brown PC as independent auditor and elected Nicholas Fernandez and Dr. Ji Yeon Baek to the Board. Crucially, stockholders authorized the Board to implement a reverse stock split at a ratio of up to 1-for-50 shares to satisfy Nasdaq listing requirements. The company operates in the biopharmaceutical industry.

Liminatus Pharma, Inc. entered into a warrant exercise inducement agreement allowing a holder to exercise 10,344,000 existing warrants at a reduced price of $0.18 per share. In exchange, the company will issue up to 20,688,000 new warrants at an exercise price of $0.18 per share, resulting in approximately $1,861,920 in gross proceeds. The company intends to use these proceeds for working capital and general corporate purposes.